Table 3.
The significant pathway enrichment analysis of downregulated DEGs
| Pathway | Term | P value | Genes |
|---|---|---|---|
| KEGG | hsa05330: allograft rejection | 4.19E−05 | CD80, GZMB, HLA-DPA1, HLA-DPB1, HLA-DOA, IL10 |
| KEGG | hsa04672: intestinal immune network for IgA production | 1.36E−04 | CD80, CCR10, HLA-DPA1, HLA-DPB1, HLA-DOA, IL10 |
| KEGG | hsa05145: toxoplasmosis | 1.64E−04 | CIITA, HLA-DPA1, JAK2, HLA-DPB1, HLA-DOA, IL10, AKT3, STAT3 |
| KEGG | hsa05320: autoimmune thyroid disease | 2.20E−04 | CD80, GZMB, HLA-DPA1, HLA-DPB1, HLA-DOA, IL10 |
| KEGG | hsa05332: graft-versus-host disease | 3.99E−04 | CD80, GZMB, HLA-DPA1, HLA-DPB1, HLA-DOA |
| KEGG | hsa04940: type I diabetes mellitus | 1.01E−03 | CD80, GZMB, HLA-DPA1, HLA-DPB1, HLA-DOA |
| KEGG | hsa05152: tuberculosis | 2.79E−03 | CIITA, HLA-DPA1, JAK2, HLA-DPB1, HLA-DOA, IL10, AKT3, CD74 |
| KEGG | hsa05416: viral myocarditis | 3.17E−03 | CD55, CD80, HLA-DPA1, HLA-DPB1, HLA-DOA |
| KEGG | hsa05310: asthma | 3.94E−03 | HLA-DPA1, HLA-DPB1, HLA-DOA, IL10 |
| KEGG | hsa05321: inflammatory bowel disease (IBD) | 4.82E−03 | HLA-DPA1, HLA-DPB1, HLA-DOA, IL10, STAT3 |
| KEGG | hsa04920: adipocytokine signaling pathway | 6.62E−03 | CD36, SOCS3, JAK2, AKT3, STAT3 |
| KEGG | hsa05140: leishmaniasis | 6.96E−03 | HLA-DPA1, JAK2, HLA-DPB1, HLA-DOA, IL10 |
| KEGG | hsa04612: antigen processing and presentation | 8.83E−03 | CIITA, HLA-DPA1, HLA-DPB1, HLA-DOA, CD74 |
| KEGG | hsa05164: influenza A | 1.08E−02 | CIITA, SOCS3, HLA-DPA1, JAK2, HLA-DPB1, HLA-DOA, AKT3 |
| KEGG | hsa04978: mineral absorption | 1.15E−02 | HMOX1, MT2A, STEAP1, MT1F |
| KEGG | hsa04062: chemokine signaling pathway | 1.46E−02 | LYN, PREX1, HCK, CCR10, JAK2, AKT3, STAT3 |
| KEGG | hsa04630: jak-STAT signaling pathway | 1.95E−02 | IL2RB, SOCS3, JAK2, IL10, AKT3, STAT3 |
| KEGG | hsa05150: staphylococcus aureus infection | 2.00E−02 | HLA-DPA1, HLA-DPB1, HLA-DOA, IL10 |
| KEGG | hsa04145: phagosome | 2.23E−02 | CD36, TFRC, TUBB6, HLA-DPA1, HLA-DPB1, HLA-DOA |
| KEGG | hsa04931: insulin resistance | 2.86E−02 | CD36, SOCS3, PTPN1, AKT3, STAT3 |
| KEGG | hsa04917: prolactin signaling pathway | 4.06E−02 | SOCS3, JAK2, AKT3, STAT3 |
| KEGG | hsa05169: epstein-Barr virus infection | 4.19E−02 | LYN, HLA-DPA1, HLA-DPB1, AKT3, STAT3 |
| KEGG | hsa05168: herpes simplex infection | 4.65E−02 | SOCS3, HLA-DPA1, JAK2, HLA-DPB1, HLA-DOA, CD74 |
| REACTOME | R-HSA-877300: interferon gamma signaling | 1.34E−05 | CIITA, TRIM2, SOCS3, MT2A, HLA-DPA1, JAK2, IRF4, HLA-DPB1 |
| REACTOME | R-HSA-982772: growth hormone receptor signaling | 5.73E−05 | LYN, SOCS3, JAK2, PTPN1, STAT3 |
| REACTOME | R-HSA-2132295: MHC class II antigen presentation | 7.94E−04 | EHHADH, CTSO, TUBB6, HLA-DPA1, HLA-DPB1, HLA-DOA, CD74 |
| REACTOME | R-HSA-389513: CTLA4 inhibitory signaling | 9.67E−04 | LYN, CD80, PPP2R5C, AKT3 |
| REACTOME | R-HSA-114604: GPVI-mediated activation cascade | 1.59E−03 | IL2RB, GAB2, LYN, JAK2, AKT3 |
| REACTOME | R-HSA-2586552: signaling by Leptin | 4.21E−03 | SOCS3, JAK2, STAT3 |
| REACTOME | R-HSA-1059683: interleukin-6 signaling | 4.21E−03 | SOCS3, JAK2, STAT3 |
| REACTOME | R-HSA-1433557: signaling by SCF-KIT | 4.43E−03 | GAB2, LYN, JAK2, STAT3 |
| REACTOME | R-HSA-877312: regulation of IFNG signaling | 6.84E−03 | SOCS3, JAK2, PTPN1 |
| REACTOME | R-HSA-392451: G beta:gamma signaling through PI3Kgamma | 9.18E−03 | IL2RB, GAB2, JAK2, AKT3 |
| REACTOME | R-HSA-912526: interleukin receptor SHC signaling | 2.45E−02 | IL2RB, GAB2, JAK2 |
| REACTOME | R-HSA-202433: generation of second messenger molecules | 4.17E−02 | ENAH, HLA-DPA1, HLA-DPB1 |